Exploring Heterocyclic Compounds: Design, Synthesis, and Their Role in Cancer, Antimicrobial Activity, and COVID-19 Treatment

Dear Colleagues,

Cancer remains one of the leading causes of mortality worldwide. The complexity and variability of cancer types necessitate innovative and effective treatment strategies. Heterocyclic compounds have shown remarkable efficacy in cancer therapy due to their ability to interact with various molecular targets involved in tumor growth and progression. Key areas where heterocyclic compounds are making significant impacts include:

• Targeted Therapy: Heterocycles can be designed to specifically inhibit cancer-related enzymes and receptors, minimizing side effects and improving treatment efficacy.
• Drug Resistance: Innovative heterocyclic structures are being developed to overcome resistance mechanisms, a major hurdle in current cancer therapies.
• Multi-Target Agents: The ability to affect multiple pathways simultaneously makes heterocyclic compounds potent candidates for complex cancer treatments.

In addition, the COVID-19 pandemic has underscored the urgent need for novel therapeutic agents to combat the virus and its variants. Heterocyclic compounds have emerged as promising candidates due to their:

• Antiviral Activity: Many heterocyclic compounds exhibit potent antiviral properties, crucial for inhibiting the replication of SARS-CoV-2.
• Immunomodulatory Effects: These compounds can modulate immune responses, potentially reducing the severity of COVID-19 symptoms and complications.
• Drug Repurposing: Existing heterocyclic drugs are being repurposed to treat COVID-19, accelerating the availability of effective treatments.

Furthermore, heterocyclic compounds have demonstrated significant antimicrobial activity, making them valuable in the fight against bacterial and fungal infections. Key areas of interest include:

• Antimicrobial Activity: The development of heterocyclic compounds with broad-spectrum antimicrobial properties to address resistant bacterial and fungal pathogens.
• Mechanistic Insights: Understanding how heterocyclic compounds exert their antimicrobial effects at the molecular level.
• Therapeutic Applications: Evaluating the potential of heterocyclic compounds as alternatives to traditional antibiotics and antifungals.

The following Special Issue aims to gather cutting-edge research and comprehensive reviews on the following topics:

• The design and synthesis of novel heterocyclic compounds for cancer, COVID-19, and antimicrobial treatment.
• Mechanistic studies on how heterocyclic compounds interact with molecular targets.
• Preclinical and clinical evaluations of heterocyclic compounds.
• Case studies on successful heterocyclic drugs in oncological, antiviral, and antimicrobial therapy.
• Computational modeling and structure–activity relationship (SAR) studies.

Dr. Sameh Abdelwahed
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.